Short-term memory of danger signals or environmental stimuli in mesenchymal stem cells: Implications for therapeutic potential

Cellular and Molecular Immunology

Volumn 13, Issue 3, 2016, Pages 369-378

  Liu, Guang Yang ^a   Liu, Yang ^b   Lu, Ying ^c   Qin, Ya Ru ^b   Di, Guo Hu ^b   Lei, Yong Hong ^d   Liu, Hu Xian ^d   Li, Yan Qi ^a   Wu, Chutse ^a,b   Hu, Xian Wen ^e   Duan, Hai Feng ^b  

^a TIANJIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c Beijing 307 Hospital   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

environmental stimuli; mesenchymal stem cells; pre conditioning; short term memory

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; CYTOKINE; DNA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MICRORNA; MICRORNA 146A; MICRORNA 150; MICRORNA 155; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 5 METHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MODIFICATION; ENVIRONMENTAL FACTOR; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RAT; SHORT TERM MEMORY; SKIN FLAP SURVIVAL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; STROMA CELL; ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CELL SHAPE; CYTOLOGY; DNA METHYLATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; IMMUNOLOGICAL MEMORY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURGICAL FLAPS; TISSUE SURVIVAL; WISTAR RAT;

5-METHYLCYTOSINE; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DNA METHYLATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICRORNAS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURGICAL FLAPS; TISSUE SURVIVAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84966429103     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.11     Document Type: Article

References (38)

1. Tomic S, Djokic J, Vasilijic S, Vucevic D, Todorovic V, Supic G et al. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by Toll-like receptor agonists. Stem Cells Dev 2011; 20: 695-708.
2. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98: 2396-2402.
3. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a proinflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010; 5: e10088.
4. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013; 13: 392-402.
5. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28: 2229-2238.
6. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008; 26: 99-107.
7. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin- Zhorov A, Cohen S et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-1432.
8. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock 2010; 33: 24-30.
9. Khan M, Akhtar S, Mohsin S, N Khan S, Riazuddin S. Growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells. Stem Cells Dev 2011; 20: 67-75.
10. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012; 11: 812-824.
11. Lee RH, Yoon N, Reneau JC, Prockop DJ. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 2012; 11: 825-835.
12. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Proinflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010; 5: e9016.
13. Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008; 26: 2173-2182.
14. Xu J, Qian J, Xie X, Lin L, Zou Y, Fu M et al. High density lipoprotein protects mesenchymal stem cells from oxidative stress-induced apoptosis via activation of the PI3K/Akt pathway and suppression of reactive oxygen species. Int J Mol Sci 2012; 13: 17104-17120.
15. Mei YB, Zhou WQ, Zhang XY, Wei XJ, Feng ZC. Lipopolysaccharides shapes the human Whartons jelly-derived mesenchymal stem cells in vitro. Cell Physiol Biochem 2013; 32: 390-401.
16. Khan M, Ali F, Mohsin S, Akhtar S, Mehmood A, Choudhery MS et al. Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart. Stem Cell Res Ther 2013; 4: 58.
17. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
18. Jaussaud J, Biais M, Calderon J, Chevaleyre J, Duchez P, Ivanovic Z et al. Hypoxia-preconditioned mesenchymal stromal cells improve cardiac function in a swine model of chronic myocardial ischaemia. Eur J Cardiothorac Surg 2013; 43: 1050-1057.
19. Yu X, Lu C, Liu H, Rao S, Cai J, Liu S et al. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One 2013; 8: e62703.
20. Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin MT. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin Sci (Lond) 2013; 124: 165-176.
21. Monticelli S, Natoli G. Short-term memory of danger signals and environmental stimuli in immune cells. Nat Immunol 2013; 14: 777-784.
22. Ozturk A, Firat C, Parlakpinar H, Bay-Karabulut A, Kirimlioglu H, Gurlek A. Beneficial effects of aminoguanidine on skin flap survival in diabetic rats. Exp Diabetes Res 2012; 2012: 721256.
23. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486.
24. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189-1201.
25. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
26. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohns disease: results of a phase I study. Gut 2010; 59: 1662-1669.
27. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-564.
28. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, MingariMC et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-648.
29. Liu N, Tian J, Cheng J, Zhang J. Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment. Exp Cell Res 2013; 319: 2019-2027.
30. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006; 125: 1111-1124.
31. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579.
32. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012; 119: 756-766.
33. Ito S, DAlessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133.
34. Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JA, Goyal P, Mahapatra S et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013; 500: 222-226.
35. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
36. van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest 2011; 121: 3877-3888.
37. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
38. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10: 176-182.